The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Open accessAbstract
Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.Methods KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy). Investigators and participants were aware of treatment assignment. Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 positivity was not required for study entry. The primary endpoints were overall survival (time from randomisation to death from any cause) and progression-free survival (time from randomisation to radiographically confirmed disease progression or death from any cause, whichever came first) in the intention-to-treat population (all participants randomly allocated to a treatment group). There were 14 primary hypotheses: superiority of pembrolizumab alone and of pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival and progression-free survival in the PD-L1 CPS of 20 or more, CPS of 1 or more, and total populations and non-inferiority (non-inferiority margin: 1·2) of pembrolizumab alone and pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival in the total population. The definitive findings for each hypothesis were obtained when statistical testing was completed for that hypothesis; this occurred at the second interim analysis for 11 hypotheses and at final analysis for three hypotheses. Safety was assessed in the as-treated population (all participants who received at least one dose of allocated treatment). This study is registered at ClinicalTrials.gov, number NCT02358031.Findings Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more. At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]). Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63-0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45-0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53-0·80], p<0·0001) at final analysis. Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis. At final analysis, grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group, 235 (85%) of 276 in the pembrolizumab with chemotherapy group, and 239 (83%) of 287 in the cetuximab with chemotherapy group. Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in the cetuximab with chemotherapy group.Interpretation Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC and pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.Funding Merck Sharp & Dohme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study of two fatal cases of myocarditis showed overexpression of cardiac proteins in the tumors of the affected patients, also potentially suggesting an overlap.18”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Self-citationPlatinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Cohen, E. E. W., Soulières, D., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M., Soria, A., Machiels, J., Mach, N., Mehra, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31999-8 · Cited by 1,737
Self-citationHead and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, D. G., Spencer, S. S., Adelstein, D. J., Adkins, D. R., Anzai, Y., Brizel, D. M., Bruce, J. Y., Busse, P. M., Caudell, J. J., Cmelak, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0031 · Cited by 1,377
Self-citationThe Efficiency of Cox's Likelihood Function for Censored Data
Efron, B. (1977) · Journal of the American Statistical Association · doi:10.1080/01621459.1977.10480613 · Cited by 1,240
Cited by
Sorted by citations
Items 201–300 of 1,002
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
Charap, A., Enokida, T., Brody, R., Sfakianos, J. P., Miles, B. A., Bhardwaj, N., & Horowitz, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001523 · Cited by 66
Tabernero, J. M., Bang, Y., Cutsem, E. V., Fuchs, C. S., Janjigian, Y. Y., Bhagia, P., Li, K., Adelberg, D. E., & Qin, S. (2021) · Future Oncology · doi:10.2217/fon-2021-0176 · Cited by 63
PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside
Nocini, R., Vianini, M., Girolami, I., Calabrese, L. S., Scarpa, A., Martini, M., Morbini, P., Marletta, S., Brunelli, M., Molteni, G., et al. (2022) · Clinical and Experimental Dental Research · doi:10.1002/cre2.590 · Cited by 63
Naing, A., Papadopoulos, K. P., Pishvaian, M. J., Rahma, O. E., Hanna, G. J., Garralda, E., Saavedra, O., Gogov, S., Kallender, H., Cheng, L., et al. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000249 · Cited by 71
A review on the advances and challenges of immunotherapy for head and neck cancer
Cheng, G., Dong, H., Yang, C., Yang, L., Wu, Y., Zhu, L., Tong, X., & Wang, S. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02024-5 · Cited by 64
Kang, J. J., Yu, Y., Chen, L., Zakeri, K., Gelblum, D. Y., McBride, S. M., Riaz, N., Tsai, C. J., Kriplani, A., Hung, T. K. W., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21758 · Cited by 63
Advancements of radiotherapy for recurrent head and neck cancer in modern era
Zhang, S., Zeng, N., Yang, J., He, J., Zhu, F., Liao, W., Xiong, M., & Li, Y. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02342-0 · Cited by 62
Machiels, J.-P., Leemans, C. R., Golusiński, W., Grau, C., Licitra, L. F., & Grégoire, V. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105042 · Cited by 61
Self-citationDzienis, M. R., Cundom, J., Fuentes, C. S., Spreafico, A., Nordlinger, M., Pastor, A. V., Alesi, E. R., Neki, A. S., Fung, A. S., Lima, I. P. F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02625 · Cited by 61
Self-citationHarrington, K. J., Champiat, S., Brody, J., Cho, B. C., Romano, E., Golan, T., Hyngstrom, J. R., Strauss, J. F., Oh, D. Y., Popovtzer, A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3630 · Cited by 61
Self-citationGrivas, P. D., Agarwal, N., Pal, S. K., Kalebasty, A. R., Sridhar, S. S., Smith, J., Devgan, G., Sternberg, C. N., & Joaquim Bellmunt, B. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102187 · Cited by 61
Botticelli, A., Zizzari, I. G., Scagnoli, S., Pomati, G., Strigari, L., Cirillo, A., Cerbelli, B., Filippo, A. D., Napoletano, C., Scirocchi, F., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070651 · Cited by 60
Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
Griso-Acevedo, A. B., Acero-Riaguas, L., Castelo, B., Carretero, J. L. C., & Sastre-Perona, A. (2022) · Cells · doi:10.3390/cells11030561 · Cited by 65
Takenaka, Y., Oya, R., Takemoto, N., & Inohara, H. (2022) · Head & Neck · doi:10.1002/hed.26997 · Cited by 64
Chung, C. H., Bonomi, M. R., Steuer, C. E., Li, J., Bhateja, P., Johnson, M., Masannat, J., Song, F., Hernandez-Prera, J. C., Wenig, B. M., et al. (2021) · Cancers · doi:10.3390/cancers13051180 · Cited by 58
Crosta, S., Boldorini, R. L., Bono, F., Brambilla, V., Dainese, E., Fusco, N., Gianatti, A., L’Imperio, V., Morbini, P., & Pagni, F. (2021) · Cancers · doi:10.3390/cancers13020292 · Cited by 59
Wang, K., Gui, L., Lu, H., He, X., Li, D., Liu, C., Liu, S., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1189752 · Cited by 59
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
Isaacs, J. M., Anders, C. K., McArthur, H. L., & Force, J. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00833-4 · Cited by 60
Veeramachaneni, R., Yu, W., Newton, J. M., Kemnade, J. O., Skinner, H. D., Sikora, A. G., & Sandulache, V. C. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002773 · Cited by 61
Guo, Y., Luo, Y., Zhang, Q., Huang, X., Li, Z., Shen, L., Feng, J., Sun, Y. P., Yang, K., Ge, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.039 · Cited by 58
Baysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 58
Galot, R., Tourneau, C. L., Saâda-Bouzid, E., Daste, A., Even, C., Debruyne, P. R., Henry, S., Zanetta, S., Rutten, A., Licitra, L. F., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.003 · Cited by 58
Self-citationBauman, J. E., Saba, N. F., Roe, D. J., Bauman, J. R., Kaczmar, J. M., Bhatia, A. K., Muzaffar, J., Julian, R. A., Wang, S., Bearelly, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01994 · Cited by 58
Self-citationCrosstalk between CAFs and tumour cells in head and neck cancer
Li, X., González-Maroto, C., & Tavassoli, M. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02053-9 · Cited by 61
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 60
Self-citationMachiels, J., Tao, Y., Burtness, B. A., Tahara, M., Licitra, L. F., Rischin, D., Waldron, J. N., Simon, C., Grégoire, V., Harrington, K. J., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0184 · Cited by 59
Self-citationTP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection
Klinakis, A., & Rampias, T. N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102905 · Cited by 59
Mo, D., Luo, P., Huang, S., Wang, H., & Huang, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107281 · Cited by 58
Self-citationLuo, R., Onyshchenko, K., Wang, L., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1591 · Cited by 61
Dong, H., Li, M., Yang, C., Wei, W., He, X., Cheng, G., & Wang, S. (2023) · Cancer Cell International · doi:10.1186/s12935-022-02846-x · Cited by 57
Rosenberg, A. J., Agrawal, N., Juloori, A., Cursio, J., Gooi, Z., Blair, E. A., Chin, J., Ginat, D. T., Pasternak-Wise, O., Hasina, R., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1530 · Cited by 57
Hanai, N., Shimizu, Y., Kariya, S., Yasumatsu, R., Yokota, T., Fujii, T., Tsukahara, K., Yoshida, M., Hanyu, K., Ueda, T., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01829-0 · Cited by 56
Self-citationMerlino, D. J., Johnson, J. M., Tuluc, M., Gargano, S., Stapp, R., Harshyne, L. A., Leiby, B. E., Flanders, A. E., Zinner, R., Axelrod, R. S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566315 · Cited by 56
Bruixola, G., Remacha, E., Jiménez-Pastor, A., Dualde, D., Viala, A., Montón-Bueno, J., Ibarrola‐Villava, M., Alberich‐Bayarri, Á., & Cervantes, A. M. R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102263 · Cited by 60
Lee, S.-Y., Shim, H. S., Ahn, B., Lim, S. M., Kim, H. R., Cho, B. C., & Hong, M. H. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03052-w · Cited by 52
Liu, S., Knochelmann, H. M., Lomeli, S. H., Hong, A., Richardson, M. S., Yang, Z., Lim, R. J., Wang, Y., Dumitras, C., Krysan, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100411 · Cited by 58
Gillison, M. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L. F., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab036 · Cited by 56
Self-citationCurrent Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges
Wise-Draper, T. M., Bahig, H., Tonneau, M., Karivedu, V., & Burtness, B. A. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350442 · Cited by 60
Self-citationFusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)
Michikawa, C., Gopalakrishnan, V., Harrandah, A. M., Karpinets, T. V., Garg, R. R., Chu, R. A., Park, Y. P., Chukkapallia, S. S., Yadlapalli, N., Erikson, K., et al. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100813 · Cited by 57
Lim, W., Kao, H., Suteja, L., Li, C. H., Quah, H. S., Tan, D. S. W., Tan, S. H., Tan, E.-H., Tan, W.-L., Lee, J. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38407-7 · Cited by 60
Self-citationLiu, Y., Wang, X., Liu, Y., Yang, J., Mao, W., Chen, F., Wu, X., Chen, X., Chen, L., & Dong, P. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06245-6 · Cited by 58
Lin, P., Xie, W., Li, Y., Zhang, C., Wu, H., Wan, H., Gao, M., Liang, F., Han, P., Chen, R., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009616 · Cited by 56
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Grünwald, V., Chirovsky, D. R., Cheung, W. Y., Bertolini, F., Ahn, M., Yang, M., de Castro, G., Berrocal, A., Sjoquist, K. M., Kuyas, H., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104526 · Cited by 56
Self-citationNiwa, K., Kawakita, D., Nagao, T., Takahashi, H., Saotome, T., Okazaki, M., Yamazaki, K., Okamoto, I., Hirai, H., Saigusa, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73965-6 · Cited by 55
Self-citationPrecision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Ortiz‐Cuaran, S., Bouaoud, J., Karabajakian, A., Fayette, J., & Saintigny, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.614332 · Cited by 59
Cao, Y., Qin, S., Luo, S., Li, Z., Cheng, Y., Fan, Y., Sun, Y., Yin, X., Yuan, X., Li, W., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100341 · Cited by 55
Immunotherapy for squamous cell carcinoma of the head and neck
Yokota, T., Homma, A., Kiyota, N., Tahara, M., Hanai, N., Asakage, T., Matsuura, K., Ogawa, T., Saito, Y., Sano, D., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa139 · Cited by 55
Self-citationTherapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma
Sun, Y., Wang, Z., Qiu, S., & Wang, R. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.58077 · Cited by 54
Lee, A., Woods, R., Mahfouz, A., Kitpanit, S., Cartano, O., Mohamed, N., Youssef, I., Marqueen, K. E., Sine, K., Mah, D. W., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.50607 · Cited by 54
Weiss, J. M., Sheth, S. H., Deal, A. M., Grilley‐Olson, J. E., Patel, S. N., Hackman, T., Blumberg, J. M., Galloway, T. J., Patel, S. A., Zanation, A. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0230 · Cited by 54
Self-citationGenome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway
Chai, A. W. Y., Yee, P. S., Price, S., Yee, S. M., Lee, H. M., Tiong, V. K., Gonçalves, E., Behan, F. M., Bateson, J., Gilbert, J. G. R., et al. (2020) · eLife · doi:10.7554/elife.57761 · Cited by 55
Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
Yu, C., Li, Q., Zhang, Y., Wen, Z., Dong, H., & Mou, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.941750 · Cited by 55
Self-citationAggarwal, C., Saba, N. F., Algazi, A. P., Sukari, A. W., Seiwert, T. Y., Haigentz, M., Porosnicu, M., Bonomi, M. R., Boyer, J., Esser, M. T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1987 · Cited by 53
Self-citationLau, A., Yang, W., Li, K. Y., & Su, Y. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102984 · Cited by 53
Self-citationAllen, S. D., Liu, X., Jiang, J., Liao, Y., Chang, C. H., Nel, A. E., & Meng, H. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120635 · Cited by 53
Fu, J., Li, W., McGrath, N., Lai, C. W., Brar, G., Xiang, Y., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 53
Gavrielatou, N., Fortis, E., Spathis, A., Anastasiou, Μ., Economopoulou, P., Foukas, G. R. P., Lelegiannis, I. M., Rusakiewicz, S., Vathiotis, I. A., Aung, T. N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.011 · Cited by 53
Self-citationThe crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies
Hu, M., Deng, F., Song, X., Zhao, H., & Yan, F. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03115-7 · Cited by 57
Liposomes-enabled cancer chemoimmunotherapy
Zhang, L., Shi, J., Zhu, M., Huang, Y., Lu, Q., Sun, P., Chen, H., Lai, X. P., & Fang, C. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122801 · Cited by 53
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Ngo, C., & Postel-Vinay, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030650 · Cited by 54
Marret, G., Bièche, I., Dupain, C., Borcoman, É., du Rusquec, P., Ricci, F., Hescot, S., Sablin, M., Tresca, P., Bello, D., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00280 · Cited by 54
Li, X., Fang, Q., Du, W., Zhang, X., Dai, L., & Qiao, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08373-8 · Cited by 53
PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
Lima, Á., de Sousa, H. M. L., Medeiros, R., Nobre, A., & Machado, M. (2022) · Discover Oncology · doi:10.1007/s12672-022-00479-0 · Cited by 51
Zhang, Y., Lin, A., Li, Y., Ding, W., Meng, H., Luo, P., & Zhang, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608969 · Cited by 51
Self-citationCheckpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
Zhou, L., Zeng, Z., Egloff, A. M., Zhang, F., Guo, F., Campbell, K. M., Du, P. P., Fu, J., Zolkind, P., Ma, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004034 · Cited by 49
Self-citationThe injury response to DNA damage in live tumor cells promotes antitumor immunity
Sriram, G., Milling, L. E., Chen, J.-K., Kong, Y. W., Joughin, B. A., Abraham, W. D., Swartwout, S., Handly, E. D., Irvine, D. J., & Yaffe, M. B. (2021) · Science Signaling · doi:10.1126/scisignal.abc4764 · Cited by 54
Wei, B., Kang, J., Kibukawa, M., Arreaza, G., Maguire, M. G., Chen, L., Qiu, P., Lang, L., Aurora-Garg, D., Cristescu, R., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.01.008 · Cited by 51
Ward, M. C., Koyfman, S. A., Bakst, R. L., Margalit, D. N., Beadle, B. M., Beitler, J. J., Chang, S. S., Cooper, J. S., Galloway, T. J., Ridge, J. A., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.03.034 · Cited by 50
Han, Y., Xu, S., Ye, W., Wang, Y., Zhang, X., Deng, J., Zhang, Z., Liu, L., & Liu, S. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04297-0 · Cited by 50
Clubb, J. H. A., Kudling, T. V., Heiniö, C., Basnet, S., Pakola, S. A., Cervera-Carrascón, V., Santos, J. M., Quixabeira, D. C. A., Havunen, R., Sorsa, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.794251 · Cited by 51
Guo, H., Ding, P., Sun, C., Yang, P., Tian, Y., Liu, Y., Lowe, S., Bentley, R., Li, Y., Zhang, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.927781 · Cited by 49
Li, Q., Chen, W., Li, Q., Mao, J., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019967 · Cited by 49
Updated Immunotherapy for Gastric Cancer
Narita, Y., & Muro, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072636 · Cited by 51
Advances in HPV‐associated tumor management: Therapeutic strategies and emerging insights
Gong, X., Chi, H., Xia, Z., Yang, G., & Tian, G. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28950 · Cited by 49
Miyazaki, N. L., Furusawa, A., Choyke, P. L., & Kobayashi, H. (2023) · Cancers · doi:10.3390/cancers15215117 · Cited by 49
Ge, J., Meng, Y., Guo, J., Chen, P., Wang, J., Shi, L., Wang, D., Qu, H., Wu, P., Fan, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52981-4 · Cited by 49
Advances and challenges in immunotherapy in head and neck cancer
Aboaid, H., Khalid, T., Hussain, A., Myat, Y. M., Nanda, R. K., Srinivasmurthy, R., Nguyen, K., Jones, D. T., Bigcas, J., & Thein, K. Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1596583 · Cited by 49
Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma
Johnson, D., & Ma, B. B. Y. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105127 · Cited by 49
Hack, S. P., Verret, W. J., Mulla, S. M., Liu, B., Wang, Y., Macarulla, T. M., Ren, Z., El-Khoueiry, A. B., & Zhu, A. X. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211036544 · Cited by 50
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma
Seliger, B., Massa, C., Yang, B., Bethmann, D., Kappler, M., Eckert, A. W., & Wickenhauser, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197032 · Cited by 48
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer
Julian, R. A., Savani, M., & Bauman, J. E. (2021) · Cancers · doi:10.3390/cancers13235889 · Cited by 51
Cohen, E. E. W., Nabell, L., Wong, D. J., Day, T., Daniels, G. A., Milhem, M. M., Deva, S., Jameson, M. B., Guntinas-Lichius, O., Almubarak, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1411 · Cited by 48
Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?
Almangush, A., Keukeleire, S. D., Rottey, S., Ferdinande, L., Vermassen, T., Leivo, I. V. V., & Mäkitie, A. A. (2022) · Cancers · doi:10.3390/cancers14061558 · Cited by 48
Poulose, J. V., & Kainickal, C. T. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i5.388 · Cited by 48
Rizvi, N. A., Ademuyiwa, F. O., Cao, Z. A., Chen, H. X., Ferris, R. L., Goldberg, S. B., Hellmann, M. D., Mehra, R., Rhee, I. P., Park, J. C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005920 · Cited by 52
Fitzsimmons, T. S., Singh, N., Walker, T. D. J., Newton, C. L., Evans, D. G., Crosbie, E. J., & Ryan, N. A. J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1192762 · Cited by 48
Statins in Cancer Prevention and Therapy
Ricco, N., & Kron, S. J. (2023) · Cancers · doi:10.3390/cancers15153948 · Cited by 53
Tahara, M., Greil, R., Rischin, D., Harrington, K. J., Burtness, B. A., de Castro, G., Psyrri, A. K., Braña, I., Neupane, P. C., Bratland, Å., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115395 · Cited by 48
Self-citationCilona, M. B., Locatello, L. G., Novelli, L., & Gallo, O. (2020) · Cancers · doi:10.3390/cancers12103006 · Cited by 49
Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
Indini, A., Rijavec, E., Ghidini, M., Tomasello, G., Cattaneo, M., Barbin, F., Bareggi, C., Galassi, B., Gambini, D., & Grossi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052628 · Cited by 48
Starzer, A. M., Berghoff, A. S., Hamacher, R., Tomasich, E., Feldmann, K., Hatziioannou, T., Traint, S., Lamm, W. W., Noebauer-Huhmann, I. M., Furtner, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001458 · Cited by 47
Gilardi, M., Saddawi‐Konefka, R., Wu, V. H., Lopez‐Ramirez, M. A., Wang, Z., Soto, F., Ramms, D. J., Proietto, M., Mikulski, Z., Miki, H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0234 · Cited by 47
Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer
Le, X., Ferrarotto, R., Wise-Draper, T. M., & Gillison, M. L. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7590 · Cited by 47
Squamous cell carcinoma of head and neck: what internists should know
Jung, K., Narwal, M., Min, S. Y., Keam, B., & Kang, H. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.078 · Cited by 52
Bourhis, J., Stein, A., Paul de Boer, J., Van Den Eynde, M., Gold, K. A., Stintzing, S., Becker, J. C., Moran, M., Schroeder, A., Pennock, G., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102172 · Cited by 47
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
Puladi, B., Ooms, M., Kintsler, S., Houschyar, K. S., Steib, F., Modabber, A., Hölzle, F., Knüchel, R., & Braunschweig, T. A. (2021) · Cancers · doi:10.3390/cancers13174409 · Cited by 48
Salvage Surgery in Recurrent Oral Squamous Cell Carcinoma
Shetty, K. S. R., Kurle, V., Greeshma, P., Ganga, V. B., Murthy, S. P., Thammaiah, S. K., Prasad, P. K., Chavan, P., Halkud, R., & Krishnappa, R. L. (2022) · Frontiers in Oral Health · doi:10.3389/froh.2021.815606 · Cited by 47
Metadata
- Authors
- Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Hong, R.-L., González Mendoza, R., Roy, A., Zhang, Y., Gumuscu, B., Cheng, J. D., Jin, F., Rischin, D., Lerzo, G., Tatangelo, M., Varela, M., Zarba, J. J., Boyer, M., Gan, H., Gao, B., Hughes, B., Mallesara, G., Rischin, D., Taylor, A., Burian, M., Fuereder, T., Greil, R., Barrios, C. H., de Castro Junior, D. O., Castro, G., Franke, F. A., Girotto, G., Lima, I. P. F., Nicolau, U. R., Pinto, G. D. J., Santos, L., Victorino, A.-P., Chua, N., Couture, F., Gregg, R., Hansen, A., Hilton, J., McCarthy, J., Soulieres, D., Ascui, R., Gonzalez, P., Villanueva, L., Torregroza, M., Zambrano, A., Holeckova, P., Kral, Z., Melichar, B., Prausova, J., Vosmik, M., Andersen, M., Gyldenkerne, N., Jurgens, H., Putnik, K., Reinikainen, P., Gruenwald, V., Laban, S., Aravantinos, G., Boukovinas, I., Georgoulias, V., Psyrri, A., Kwong, D., Al-Farhat, Y., Csoszi, T., Erfan, J., Horvai, G., Landherr, L., Remenar, E., Ruzsa, A., Szota, J., Billan, S., Gluck, I., Gutfeld, O., Popovtzer, A., Benasso, M., Bui, S., Ferrari, V., Licitra, L., Nole, F., Fujii, T., Fujimoto, Y., Hanai, N., Hara, H., Matsumoto, K., Mitsugi, K., Monden, N., Nakayama, M., Okami, K., Oridate, N., Shiga, K., Shimizu, Y., Sugasawa, M., Tahara, M., Takahashi, M., Takahashi, S., Tanaka, K., Ueda, T., Yamaguchi, H., Yamazaki, T., Yasumatsu, R., Yokota, T., Yoshizaki, T., Kudaba, I., Stara, Z., Wan Ishak, W. Z., Cheah, S. K., Aguilar Ponce, J., Gonzalez Mendoza, R., Hernandez Hernandez, C., Medina Soto, F., Buter, J., Hoeben, A., Oosting, S., Suijkerbuijk, K., Bratland, A., Brydoey, M., Alvarez, R., Mas, L., Caguioa, P., Querol, J., Regala, E. E., Tamayo, M. B., Villegas, E. M., Kawecki, A., Karpenko, A., Klochikhin, A., Smolin, A., Zarubenkov, O., Goh, B. C., Cohen, G., du Toit, J., Jordaan, C., Landers, G., Ruff, P., Szpak, W., Tabane, N., Brana, I., Iglesias Docampo, L., Lavernia, J., Mesia, R., Abel, E., Muratidu, V., Nielsen, N., Cristina, V., Rordorf, T., Rothschild, S., Hong, R.-L., Wang, H.-M., Yang, M.-H., Yeh, S.-P., Yen, C.-J., Ngamphaiboon, N., Soparattanapaisarn, N., Sriuranpong, V., Aksoy, S., Cicin, I., Ekenel, M., Harputluoglu, H., Ozyilkan, O., Harrington, K., Agarwala, S., Ali, H., Alter, R., Anderson, D., Bruce, J., Burtness, B., Campbell, N., Conde, M., Deeken, J., Edenfield, W., Feldman, L., Gaughan, E., Goueli, B., Halmos, B., Hegde, U., Hunis, B., Jotte, R., Karnad, A., Khan, S., Laudi, N., Laux, D., Martincic, D., McCune, S., McGaughey, D., Misiukiewicz, K., Mulford, D., Nadler, E., Neupane, P., Nunnink, J., Ohr, J., O'Malley, M., Patson, B., Paul, D., Popa, E., Powell, S., Redman, R., Rella, V., Rocha Lima, C., Sivapiragasam, A., Su, Y., Sukari, A., Wong, S., Yilmaz, E., & Yorio, J.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Oslo University Hospital (NO)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Mahidol University (TH)
- Paracelsus Medical University (AT)
- National Cancer Center Hospital East (JP)
- The University of Melbourne (AU)
- Autonomous University of Chihuahua (MX)
- ORCID
- Basté, Neus
- Bratland, Åse
- Roy, Ananya
- Jin, Fan
- Boyer, Michael
- Gan, Hui
- Gao, Bo
- Mallesara, Girish
- Burian, Martin
- Barrios, Carlos Henrique
- Franke, Fabio Andre
- Girotto, Gustavo
- Nicolau, Ulisses Ribaldo
- Pinto, Gustavo Dix Junqueira
- Santos, Lucas
- Victorino, Ana-Paula
- Chua, Neil
- Gregg, Richard
- Hansen, Aaron
- Hilton, John
- Zambrano, Angela
- Melichar, Bohuslav
- Andersen, Maria
- Reinikainen, Petri
- Laban, Simon
- Aravantinos, Gerasimos
- Boukovinas, Ioannis
- Billan, Salem
- Popovtzer, Aron
- Bui, Simona
- Licitra, Lisa
- Fujii, Takashi
- Fujimoto, Yasushi
- Hanai, Nobuhiro
- Hara, Hiroki
- Matsumoto, Koji
- Monden, Nobuya
- Nakayama, Masahiro
- Okami, Kenji
- Oridate, Nobuhiko
- Shiga, Kiyoto
- Shimizu, Yasushi
- Sugasawa, Masashi
- Takahashi, Masanobu
- Takahashi, Shunji
- Tanaka, Kaoru
- Ueda, Tsutomu
- Yamaguchi, Hironori
- Yamazaki, Tomoko
- Yasumatsu, Ryuji
- Yokota, Tomoya
- Yoshizaki, Tomokazu
- Buter, Jan
- Hoeben, Ann
- Oosting, S.
- Suijkerbuijk, Karijn
- Mas, Luis
- Caguioa, Priscilla
- Kawecki, Andrzej
- Klochikhin, Arkadiy
- Smolin, Alexey
- Goh, Boon Cher
- Cohen, Graham
- Ruff, Paul
- Szpak, Waldemar
- Lavernia, Javier
- Abel, Edvard
- Rothschild, Sacha
- Wang, Hung-Ming
- Yang, Muh-Hwa
- Yeh, Su-Peng
- Yen, Chia-Jui
- Sriuranpong, Virote
- Aksoy, Sercan
- Ekenel, Meltem
- Agarwala, Sanjiv
- Ali, Haythem
- Alter, Robert
- Anderson, Daniel
- Bruce, Justine
- Campbell, Nicholas
- Conde, Miguel
- Deeken, John
- Feldman, Lawrence
- Gaughan, Elizabeth
- Hegde, Upendra
- Jotte, Robert
- Karnad, Anand
- Khan, Saad
- Laudi, Noel
- Laux, Douglas
- McCune, Steven
- Misiukiewicz, Krzysztof
- Nadler, Eric
- Ohr, James
- Paul, Doru
- Powell, Steven
- Sivapiragasam, Abirami
- Sukari, Ammar
- Wong, Stuart
- Yilmaz, Emrullah
- Yorio, Jeffrey
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 394
- Issue
- 10212
- Pages
- 1915-1928
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2986633517
- Cited by
- 3,336
- References
- 25
- Citations by year
- 2026: 434 · 2025: 551 · 2024: 549 · 2023: 522 · 2022: 535 · 2021: 465 · 2020: 270 · 2019: 5
- FWCI
- 268.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Regeneron Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Eisai
- Japan Society for the Promotion of Science (17H01590, 17K19718)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- cetuximab, head and neck squamous cell carcinoma, recurrent or metastatic cancer, PD-L1 expression, PD-L1 combined positive score, immune checkpoint inhibitors, overall survival, progression-free survival, non-inferiority, p16 status, treatment safety
- MeSH terms
- Cetuximab, Antineoplastic Agents, Immunological, Squamous Cell Carcinoma of Head and Neck, Progression-Free Survival, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Female, Fluorouracil, Head and Neck Neoplasms, Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
